Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accumulated Depreciation (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Accumulated Depreciation for 3 consecutive years, with $1.1 million as the latest value for Q2 2025.

  • On a quarterly basis, Accumulated Depreciation changed N/A to $1.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $1.1 million, a N/A change, with the full-year FY2024 number at $949000.0, up 18.63% from a year prior.
  • Accumulated Depreciation was $1.1 million for Q2 2025 at Mereo BioPharma, up from $949000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.1 million in Q2 2025 to a low of $800000.0 in Q4 2023.
  • A 3-year average of $955750.0 and a median of $956500.0 in 2024 define the central range for Accumulated Depreciation.
  • Biggest YoY gain for Accumulated Depreciation was 18.63% in 2024; the steepest drop was 18.63% in 2024.
  • Mereo BioPharma's Accumulated Depreciation stood at $800000.0 in 2023, then grew by 18.62% to $949000.0 in 2024, then rose by 16.97% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Accumulated Depreciation are $1.1 million (Q2 2025), $949000.0 (Q4 2024), and $964000.0 (Q3 2024).